LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU=von Vajna Erika AU=von Vajna Erika
  2. AU=Isac Chandrani
  3. AU="Henning, Amanda N"
  4. AU="Bokacheva, Louisa"
  5. AU="Bennett, Kevin J"
  6. AU="Wu, J" AU="Wu, J"
  7. AU="Kotsubo, Vincent Y"
  8. AU="Sladek, Frances M"
  9. AU="Sevillya, Gur"
  10. AU="Jia, Jinhui"
  11. AU="Valero, Sergi"
  12. AU="Lu, Chia-Jung"
  13. AU="Patel, Nakul"
  14. AU=Cerdena Jessica P
  15. AU="Cano, Suzana Faria"
  16. AU="Richardson, Kathryn"
  17. AU="Tsourouflis, Gerassimos"
  18. AU="Srai, S K"
  19. AU="Or, Charles C-F"
  20. AU="Rohin, Francis"
  21. AU="Natália Pinto de Almeida"
  22. AU="Spagnolo-Allende, Antonio J"
  23. AU="Jenninger, B"
  24. AU="Kerenza Hood"
  25. AU="Khan Chachar, Aijaz Zeeshan"
  26. AU="Yuan, Weiming"

Suchergebnis

Treffer 1 - 1 von insgesamt 1

Suchoptionen

Artikel: Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population.

von Vajna, Erika / Alam, Ruhaniyah / So, Tsz-Yin

Cardiology and therapy

2016  Band 5, Heft 1, Seite(n) 19–41

Abstract: Common treatment options for deep vein thrombosis and venous thromboembolism in the pediatric population include unfractionated heparin, low molecular weight heparin, and warfarin. Other alternatives are bivalirudin, argatroban, and fondaparinux. ... ...

Abstract Common treatment options for deep vein thrombosis and venous thromboembolism in the pediatric population include unfractionated heparin, low molecular weight heparin, and warfarin. Other alternatives are bivalirudin, argatroban, and fondaparinux. Warfarin is the only approved oral option, but an oral agent without frequent monitoring would be optimal for pediatric patients. Thus, there is an increasing need for new anticoagulation options in this population. None of the current direct oral anticoagulants have FDA-approved indications and dosing in children. The two classes of DOACs and the drugs they are comprised of are factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and direct thrombin inhibitor (dabigatran). Off-label usage of these agents is largely based on adult doses. By far, rivaroxaban and dabigatran have the most published data and ongoing trials in pediatric patients compared to edoxaban and apixaban. After evaluating the current literature available on these agents, it is, however, still too early to make any definitive recommendations on their usage in this special population.
Sprache Englisch
Erscheinungsdatum 2016-01-06
Erscheinungsland England
Dokumenttyp Journal Article ; Review
ZDB-ID 2700626-8
ISSN 2193-6544 ; 2193-8261
ISSN (online) 2193-6544
ISSN 2193-8261
DOI 10.1007/s40119-015-0054-y
Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Kategorien

Zum Seitenanfang